6th International Immunoglobulin Symposium: Poster presentations

The posters presented at the 6th International Immunoglobulin Symposium covered a wide range of fields and included both basic science and clinical research. From the abstracts accepted for poster presentation, 12 abstracts were selected for oral presentations in three parallel sessions on immunodeficiencies, autoimmunity and basic research. The immunodeficiency presentations dealt with novel, rare class‐switch recombination (CSR) deficiencies, attenuation of adverse events following IVIg treatment, association of immunoglobulin (Ig)G trough levels and protection against acute infection in patients with X‐linked agammaglobulinaemia (XLA) and common variable immunodeficiency (CVID), and the reduction of class‐switched memory B cells in patients with specific antibody deficiency (SAD). The impact of intravenous immunoglobulin on fetal alloimmune thrombocytopenia, pregnancy and postpartum‐related relapses in multiple sclerosis and refractory myositis, as well as experiences with subcutaneous immunoglobulin in patients with multi‐focal motor neuropathy, were the topics presented in the autoimmunity session. The interaction of dendritic cell (DC)‐SIGN and α2,6‐sialylated IgG Fc and its impact on human DCs, the enrichment of sialylated IgG in plasma‐derived IgG, as wells as prion surveillance and monitoring of anti‐measles titres in immunoglobulin products, were covered in the basic science session. In summary, the presentations illustrated the breadth of immunoglobulin therapy usage and highlighted the progress that is being made in diverse areas of basic and clinical research, extending our understanding of the mechanisms of immunoglobulin action and contributing to improved patient care.

[1]  F. Bonilla Intravenous immunoglobulin: adverse reactions and management. , 2008, The Journal of allergy and clinical immunology.

[2]  P. Modrich,et al.  Endonucleolytic Function of MutLα in Human Mismatch Repair , 2006, Cell.

[3]  S. Kaveri,et al.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.

[4]  A. Fischer,et al.  Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination , 2008, The Journal of experimental medicine.

[5]  J. Kelton,et al.  Diagnosis and management of neonatal alloimmune thrombocytopenia. , 2008, Transfusion medicine reviews.

[6]  J. Huggins,et al.  Use of intravenous immunoglobulin G (IVIG). , 2006, Best practice & research. Clinical haematology.

[7]  M. Hutchinson,et al.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.

[8]  M. Ballow Safety of IGIV therapy and infusion-related adverse events , 2007, Immunologic research.

[9]  P. Modrich,et al.  Endonucleolytic function of MutLalpha in human mismatch repair. , 2006, Cell.

[10]  V. Wahn,et al.  Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success , 2005, International Archives of Allergy and Immunology.

[11]  R. Hughes,et al.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy * , 2006, European journal of neurology.

[12]  M. Berger Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency , 2008, Immunology and Allergy Clinics of North America.

[13]  A. Gabrielli,et al.  [Intravenous immunoglobulin treatment in autoimmune diseases]. , 2007, Recenti progressi in medicina.

[14]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[15]  H. Isliker,et al.  Intravenous Administration of Human γ‐Globulin * , 1962 .

[16]  S. Kaveri,et al.  DC-SIGN and α2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells , 2009, Proceedings of the National Academy of Sciences.

[17]  R. Berkowitz,et al.  Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia , 2006, Obstetrics and gynecology.

[18]  A. Fischer,et al.  Human uracil–DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination , 2003, Nature Immunology.

[19]  Christian Confavreux,et al.  Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. , 2004, Brain : a journal of neurology.

[20]  M. Turner,et al.  An update on the assessment and management of the risk of transmission of variant Creutzfeldt‐Jakob disease by blood and plasma products , 2009, British journal of haematology.

[21]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[22]  M. Hutchinson,et al.  Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .

[23]  R. Berkowitz,et al.  Alloimmune thrombocytopenia: state of the art 2006. , 2006, American journal of obstetrics and gynecology.